Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative

Area of Science:

• Epigenetics and Molecular Biology
• Medicinal Chemistry
• Cancer Therapeutics

Background:

• Bromodomain-containing protein 4 (BRD4) is vital for epigenetic gene regulation, making it a therapeutic target in oncology.
• Existing BRD4 inhibitors face challenges with clinical drug resistance.
• Proteolysis Targeting Chimeras (PROTACs) offer a novel approach to degrade target proteins and potentially overcome resistance.

Purpose of the Study:

• To design, synthesize, and evaluate novel pyrrolopyridone derivative-based BRD4 degraders.
• To assess the efficacy of these degraders in inhibiting tumor growth and overcoming drug resistance.
• To investigate the molecular mechanisms underlying the anti-cancer activity of the developed compounds.

Main Methods:

• Synthesis of novel pyrrolopyridone derivatives.
• In vitro evaluation of BRD4 degradation and inhibition using biochemical assays (IC50).
• Assessment of anti-proliferative activity against cancer cell lines (e.g., BxPC3).
• Analysis of downstream effects including c-Myc inhibition, cell cycle arrest, and apoptosis induction.

Main Results:

• Four synthesized compounds demonstrated potent inhibition of BRD4 BD1 at low nanomolar concentrations.
• Compound 32a exhibited significantly improved anti-proliferative activity (7-fold) compared to a known BRD4 inhibitor (ABBV-075) in BxPC3 cells.
• Degrader 32a effectively induced BRD4 degradation and suppressed c-Myc expression in a time-dependent manner.
• 32a triggered cell cycle arrest and apoptosis, indicating a robust anti-tumor mechanism.

Conclusions:

• Pyrrolopyridone derivative-based compounds are effective BRD4 degraders.
• Compound 32a shows significant potential as a therapeutic agent for cancer treatment due to its potent degradation of BRD4 and induction of apoptosis.
• Further investigation of compound 32a is warranted for its clinical application in overcoming BRD4 inhibitor resistance.